35 Percent of Eligible Children Receive RSV Prophylaxis With Nirsevimab
By Elana Gotkine HealthDay Reporter
TUESDAY, July 22, 2025 -- Despite near universal availability of nirsevimab, only 35 percent of eligible children receive nirsevimab for respiratory syncytial virus (RSV) prophylaxis, according to a study published online July 17 in Pediatrics.
Mahaa M. Ahmed, from the Children's Hospital of Philadelphia, and colleagues examined the distribution of nirsevimab to determine factors associated with receipt of nirsevimab among children younger than 8 months attending one of 32 pediatric primary care practices with almost universal nirsevimab eligibility.
Overall, 35 percent of 7,208 eligible patients received nirsevimab, varying from 20 to 65 percent across practices. The researchers found that the rates of nirsevimab receipt were lower in association with older age (odds ratio, 0.60 for each additional month), Black race (odds ratio, 0.53 versus White infants), very low Child Opportunity Index (COI) scores (odds ratio, 0.70 versus very high COI), and public insurance (0.79 versus private insurance).
"The identification of sociodemographic factors associated with receipt of nirsevimab emphasizes the importance of examining the drivers of these disparities to inform interventions designed to ensure more equitable uptake so that all children are protected from RSV," the authors write.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted July 2025
Read this next
Tdap, MenACWY Coverage Increased in Teens From 2023 to 2024
TUESDAY, Aug. 19, 2025 -- From 2023 to 2024, coverage with one or more doses of the tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine (Tdap) and the...
Two Doses of Zoster Vaccine Reduce Risk for Herpes Zoster Ophthalmicus
TUESDAY, Aug. 19, 2025 -- Two doses of recombinant zoster vaccine (RZV) are associated with a reduced risk for herpes zoster ophthalmicus (HZO), acute myocardial infarction, and...
Public Awareness Low About HPV, HPV Vaccination, HPV-Linked Cancer
THURSDAY, Aug. 14, 2025 -- Public awareness about human papillomavirus (HPV), HPV vaccination, and HPV-associated cancers is low, according to a research letter published online...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.